Inclusion Criteria:

          -  Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic
             solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement

          -  For patients enrolled via local molecular testing, an archival or fresh tumor tissue
             (unless medically contraindicated) is required to be submitted for independent central
             molecular testing at Ignyta's CLIA laboratory post-enrollment

          -  Measurable or evaluable disease

          -  Patients with CNS involvement, including leptomeningeal carcinomatosis, which is
             either asymptomatic or previously-treated and controlled, are allowed

          -  Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1,
             or ALK inhibitors in patients who have tumors that harbor those respective gene
             rearrangements)

             - Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged
             NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are
             prohibited.

          -  At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior
             chemotherapy or small molecule targeted therapy

          -  At least 4 weeks must have elapsed since completion of antibody-directed therapy

          -  Prior radiotherapy is allowed if more than 14 days have elapsed since the end of
             treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life
             expectancy of 4 weeks

          -  Adequate organ function as defined per protocol

          -  Ability to swallow entrectinib intact

          -  Other protocol specified criteria

        Exclusion Criteria:

          -  Current participation in another therapeutic clinical trial

          -  Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in
             patients who have tumors that harbor those respective gene rearrangements

             - Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged
             NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are
             prohibited.

          -  History of other previous cancer that would interfere with the determination of safety
             or efficacy

          -  Familial or personal history of congenital bone disorders, or bone metabolism
             alterations

          -  Incomplete recovery from any surgery

          -  History of recent (within the past 3 months) symptomatic congestive heart failure or
             ejection fraction ≤50% observed during screening for the study

          -  History of non-pharmacologically induced prolonged QTc interval

          -  History of additional risk factors for torsades de pointes

          -  Peripheral neuropathy Grade ≥ 2

          -  Known active infections

          -  Active gastrointestinal disease or other malabsorption syndromes

          -  Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase
             inhibitor-induced pneumonitis

          -  Other protocol specified criteria